A double-blind, randomized, multicenter, placebo-controlled, parallel, dose-titration study to assess the efficacy of lercanidipine 10mg and 20mg once daily p.o. in hypertensive subjects (I or II WHO [World health Organisation]) with elevated body weight.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Lercanidipine (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 16 Jul 2007 Status changed from in progress to completed.
- 14 Nov 2005 New trial record.